Head to Head Review: NeuroBo Pharmaceuticals (NASDAQ:NRBO) vs. Ainos (NASDAQ:AIMD)

NeuroBo Pharmaceuticals (NASDAQ:NRBO) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Institutional and Insider Ownership

1.4% of NeuroBo Pharmaceuticals shares are held by institutional investors. 0.8% of NeuroBo Pharmaceuticals shares are held by insiders. Comparatively, 4.6% of Ainos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares NeuroBo Pharmaceuticals and Ainos’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroBo Pharmaceuticals	N/A	N/A	-$12.47 million	N/A	N/A
Ainos	$120,000.00	52.70	-$13.77 million	($2.55)	-0.40

NeuroBo Pharmaceuticals has higher earnings, but lower revenue than Ainos.

Volatility and Risk

NeuroBo Pharmaceuticals has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500. Comparatively, Ainos has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for NeuroBo Pharmaceuticals and Ainos, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroBo Pharmaceuticals	0	0	0	0	N/A
Ainos	0	0	0	0	N/A

Profitability

This table compares NeuroBo Pharmaceuticals and Ainos’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroBo Pharmaceuticals	N/A	-59.42%	-45.40%
Ainos	-11,205.49%	-47.96%	-40.37%

Summary

Ainos beats NeuroBo Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

About Ainos

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.